Multiple Sclerosis in the UK: Service Use, Costs, Quality of Life and Disability

Author： McCrone Paul  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.26, Iss.10, 2008-01, pp. : 847-860

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The forgotten costs of multiple sclerosis

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 347, 2002-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

The use of cannabinoids in multiple sclerosis

By Teare Lara   Zajicek John  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 7, 2005-07 ,pp. : 859-869

Informa Healthcare

Access to resources Recommend Favorite

Health-Related Quality of Life in Multiple Sclerosis: Current Evidence, Measurement and Effects of Disease Severity and Treatment

By Rudick Richard A.   Miller Deborah M.  

CNS Drugs, Vol. 22, Iss. 10, 2008-01 ,pp. : 827-839

Adis International

Access to resources Recommend Favorite

Economic Evaluation of Multiple Sclerosis in the UK, Germany and France

By Murphy N.  

PharmacoEconomics, Vol. 13, Iss. 5, 1998-05 ,pp. : 607-622

Adis International

Access to resources Recommend Favorite

Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability

By Panitch Hillel   Applebee Angela  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 10, 2011-07 ,pp. : 1511-1521

Informa Healthcare

Access to resources Recommend Favorite